(Total Views: 336)
Posted On: 11/14/2019 9:03:03 AM
Post# of 149265
aidenb, I wanted to follow-up and provide the statement and link to the PR I was referencing, but didn't have time to look it up yesterday when posting from my phone.
It's from the May 8th PR: CytoDyn Provides Updated Pre-Clinical Data Showing Leronlimab (PRO 140) Continues to Suppress Breast Cancer Metastatic Burden >98% Compared with Untreated Animals
https://www.cytodyn.com/newsroom/press-releas...ta-showing
Quote:
With recently granted Fast Track Designation for mTNBC, Section 561A(f)(2) of the FD&C Act, now requires leronlimab to be available within 15 days under expanded access policy for patients with serious or life-threatening illnesses
It's from the May 8th PR: CytoDyn Provides Updated Pre-Clinical Data Showing Leronlimab (PRO 140) Continues to Suppress Breast Cancer Metastatic Burden >98% Compared with Untreated Animals
https://www.cytodyn.com/newsroom/press-releas...ta-showing
(0)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
Scroll down for more posts ▼
